Molecular Mechanism of Astragaloside IV in Improving Endothelial Dysfunction of Cardiovascular Diseases Mediated by Oxidative Stress

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2021 Nov 29

PMID 34840664

Citations 9

Authors

Peipei Meng

Rui Yang

Fenjun Jiang

Jianbo Guo

Xinyu Lu

Tao Yang

Qingyong He

Affiliations

Soon will be listed here.

Abstract

Endothelial dysfunction, induced by oxidative stress, is an essential factor affecting cardiovascular disease. Uncoupling of endothelial nitric oxide synthase (eNOS) leads to a decrease in nitric oxide (NO) production, an increase in reactive oxygen species (ROS) production, NO consumption, and NO synthesis. As a main active ingredient of astragalus, astragaloside IV can reduce the apoptosis of endothelial cells during oxidative stress. This review is aimed at exploring the mechanism of astragaloside IV in improving oxidative stress-mediated endothelial dysfunction relevant to cardiovascular diseases. The findings showed that the astragaloside IV can prevent or reverse the uncoupling of eNOS, increase eNOS and NO, and enhance several activating enzymes to activate the antioxidant system. In-depth validation and quantitative experiments still need to be implemented.

Citing Articles

Astragaloside IV attenuates glucocorticoid-induced osteoclastogenesis and bone loss via the MAPK/NF-κB pathway.

Guo C, Li Y, Yang R, Xie M, Chen X, Che Z BMC Complement Med Ther. 2025; 25(1):48.

PMID: 39934767 PMC: 11818135. DOI: 10.1186/s12906-025-04793-2.

Analysis of the predictive value of microRNA-199b-5p combined with nitric oxide for venous thrombosis in patients undergoing total knee arthroplasty.

Zhou S, Ma W, Li Y, Liu L, Lu S J Orthop Surg Res. 2024; 19(1):505.

PMID: 39182115 PMC: 11344363. DOI: 10.1186/s13018-024-04997-1.

Astragaloside IV Reduces Lung Epithelial Cell Pyroptosis via TXNIP-NLRP3-GSDMD pathway.

Wu K, Luan G, Hu J, Zhu Z, Kong Z, Yin S Cell Biochem Biophys. 2024; 82(4):3695-3702.

PMID: 39096465 DOI: 10.1007/s12013-024-01457-9.

The Antioxidant Action of : Its Active Components and Molecular Basis.

Yao J, Peng T, Shao C, Liu Y, Lin H, Liu Y Molecules. 2024; 29(8).

PMID: 38675511 PMC: 11052376. DOI: 10.3390/molecules29081691.

A systematic review of astragaloside IV effects on animal models of diabetes mellitus and its complications.

Qu C, Tan X, Hu Q, Tang J, Wang Y, He C Heliyon. 2024; 10(5):e26863.

PMID: 38439832 PMC: 10909731. DOI: 10.1016/j.heliyon.2024.e26863.

References

Miyazaki T, Miyazaki A . Dysregulation of Calpain Proteolytic Systems Underlies Degenerative Vascular Disorders. J Atheroscler Thromb. 2017; 25(1):1-15. PMC: 5770219. DOI: 10.5551/jat.RV17008. View

Pan Y, Jia X, Song E, Peng X . Astragaloside Ⅳ Protects Against Aβ1-42-induced Oxidative Stress, Neuroinflammation and Cognitive Impairment in Rats. Chin Med Sci J. 2018; 33(1):29-37. DOI: 10.24920/11802. View

Kalinowski L, Malinski T . Endothelial NADH/NADPH-dependent enzymatic sources of superoxide production: relationship to endothelial dysfunction. Acta Biochim Pol. 2004; 51(2):459-69. View

Keum Y, Choi B . Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway. Molecules. 2014; 19(7):10074-89. PMC: 6270911. DOI: 10.3390/molecules190710074. View

Mittler R . Oxidative stress, antioxidants and stress tolerance. Trends Plant Sci. 2002; 7(9):405-10. DOI: 10.1016/s1360-1385(02)02312-9. View

Meza C, La Favor J, Kim D, Hickner R . Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS?. Int J Mol Sci. 2019; 20(15). PMC: 6696313. DOI: 10.3390/ijms20153775. View

Virdis A, Ghiadoni L, Taddei S . Human endothelial dysfunction: EDCFs. Pflugers Arch. 2010; 459(6):1015-23. DOI: 10.1007/s00424-009-0783-7. View

Ji K, Chen J, Hu J, Xue Y, Yin R, Lu Q . The protective effect of astragaloside IV against benzo[a]pyrene induced endothelial progenitor cell dysfunction. Life Sci. 2015; 132:13-9. DOI: 10.1016/j.lfs.2015.04.002. View

Jia Y, Zuo D, Li Z, Liu H, Dai Z, Cai J . Astragaloside IV inhibits doxorubicin-induced cardiomyocyte apoptosis mediated by mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. Chem Pharm Bull (Tokyo). 2014; 62(1):45-53. DOI: 10.1248/cpb.c13-00556. View

10.

Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H . The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000; 275(33):25781-90. DOI: 10.1074/jbc.M001235200. View

11.

Nie Q, Zhu L, Zhang L, Leng B, Wang H . Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation. Life Sci. 2019; 232:116662. DOI: 10.1016/j.lfs.2019.116662. View

12.

Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H . Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol. 2012; 11:46. PMC: 3403843. DOI: 10.1186/1475-2840-11-46. View

13.

You L, Fang Z, Shen G, Wang Q, He Y, Ye S . Astragaloside IV prevents high glucose‑induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells. Mol Med Rep. 2019; 19(3):1603-1612. PMC: 6390021. DOI: 10.3892/mmr.2019.9812. View

14.

Etelainen T, Kulmala V, Svarcbahs R, Jantti M, Myohanen T . Prolyl oligopeptidase inhibition reduces oxidative stress via reducing NADPH oxidase activity by activating protein phosphatase 2A. Free Radic Biol Med. 2021; 169:14-23. DOI: 10.1016/j.freeradbiomed.2021.04.001. View

15.

Xu C, Tang F, Lu M, Yang J, Han R, Mei M . Pretreatment with Astragaloside IV protects human umbilical vein endothelial cells from hydrogen peroxide induced oxidative stress and cell dysfunction via inhibiting eNOS uncoupling and NADPH oxidase - ROS - NF-κB pathway. Can J Physiol Pharmacol. 2016; 94(11):1132-1140. DOI: 10.1139/cjpp-2015-0572. View

16.

Lin X, Cui H, Yang A, Luo J, Tang T . Astragaloside IV Improves Vasodilatation Function by Regulating the PI3K/Akt/eNOS Signaling Pathway in Rat Aorta Endothelial Cells. J Vasc Res. 2018; 55(3):169-176. DOI: 10.1159/000489958. View

17.

Leng B, Li C, Sun Y, Zhao K, Zhang L, Lu M . Protective Effect of Astragaloside IV on High Glucose-Induced Endothelial Dysfunction via Inhibition of P2X7R Dependent P38 MAPK Signaling Pathway. Oxid Med Cell Longev. 2020; 2020:5070415. PMC: 7512101. DOI: 10.1155/2020/5070415. View

18.

Zhang Z, Wu L, Wang J, Yang J, Zhang J, Zhang J . Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. Mol Cell Biochem. 2012; 364(1-2):209-16. DOI: 10.1007/s11010-011-1219-1. View

19.

Wang B, Zhang C, Chu D, Ma X, Yu T, Liu X . Astragaloside IV improves angiogenesis under hypoxic conditions by enhancing hypoxia‑inducible factor‑1α SUMOylation. Mol Med Rep. 2021; 23(4). PMC: 7893755. DOI: 10.3892/mmr.2021.11883. View

20.

Jiang P, Ma D, Wang X, Wang Y, Bi Y, Yang J . Astragaloside IV Prevents Obesity-Associated Hypertension by Improving Pro-Inflammatory Reaction and Leptin Resistance. Mol Cells. 2018; 41(3):244-255. PMC: 5881098. DOI: 10.14348/molcells.2018.2156. View